Zealand Pharma

This Phase 2 trial tests a once-weekly injection called petrelintide in 221 people with overweight or obesity and type 2 diabetes. Participants receive either petrelintide or a placebo for several weeks. The main goal is to see how much weight they lose and whether blood sugar im…

This study tests the long-term safety and effectiveness of a weekly injection called glepaglutide in adults with short bowel syndrome, a condition where the body cannot absorb nutrients properly. Participants who completed a previous trial will receive the drug for about 2 years.…

This phase 3 trial tests the long-term safety of glepaglutide, a drug that mimics a natural gut hormone, in 145 adults with short bowel syndrome. The goal is to see if it can safely help the gut absorb more nutrients, potentially reducing the need for intravenous feeding. Partici…

This study is testing the long-term safety of dasiglucagon, a drug given as a continuous injection under the skin, in children with congenital hyperinsulinism (a condition causing dangerously low blood sugar). The trial includes 42 children who completed earlier studies. Research…

This study tested a new weekly injection called petrelintide to help people with obesity or overweight (plus related health issues) lose weight. About 493 participants received either the drug or a placebo, along with diet and exercise advice, for 28 weeks. The main goal was to s…

This early-stage study tested a single injection of petrelintide, a potential weight-management drug, in 48 adults with a BMI of 27 or higher. Researchers wanted to see if using different concentrations of the drug changed how the body processes it or affected safety. Participant…

This study tested a new weight-management drug called petrelintide in 39 people with normal or impaired kidney function. Researchers wanted to see if kidney problems change how the drug behaves in the body. The goal is to guide safe dosing for people with kidney issues who might …